Haefely W
Neurosci Lett. 1984 Jun 29;47(3):201-6. doi: 10.1016/0304-3940(84)90514-7.
Benzodiazepines (BZs) produce most, if not all, of their pharmacological actions by specifically enhancing the effects of endogenous and exogenous GABA that are mediated by GABAA receptors. This potentiation consists in an increase of the apparent affinity of GABA for increasing chloride conductance without increase in its efficacy and, on the single chloride channel level, seems to be the result of an increased probability of channel opening events. Recent studies indicate that the BZR is a site on the GABA receptor (GABA-R)-chloride channel complex, through which the gain of the signal transducer function of the latter is allosterically modulated. The unique feature of this drug receptor, which is located on a neurotransmitter receptor-gated ion channel, is its specific interaction with three classes of ligands. Agonists, competitive antagonists and inverse agonists at BZR, respectively increase, do not alter and reduce the gain of the GABA-R function. Compounds have been found that cover a whole spectrum of transition between the two extremes (partial agonists, partial inverse agonists) and for which interesting therapeutic applications can be foreseen.
苯二氮䓬类药物(BZs)即便不是全部,其大部分药理作用都是通过特异性增强由GABAA受体介导的内源性和外源性γ-氨基丁酸(GABA)的作用来实现的。这种增强作用表现为GABA对增加氯离子电导的表观亲和力增加,而其效能并未增加,并且在单个氯离子通道水平上,似乎是通道开放事件概率增加的结果。最近的研究表明,苯二氮䓬受体(BZR)是GABA受体(GABA-R)-氯离子通道复合物上的一个位点,通过该位点,后者信号转导功能的增益受到变构调节。这种位于神经递质受体门控离子通道上的药物受体的独特之处在于它与三类配体的特异性相互作用。BZR上的激动剂、竞争性拮抗剂和反向激动剂分别增加、不改变和降低GABA-R功能的增益。已经发现了一些化合物,它们涵盖了这两个极端之间的整个转变范围(部分激动剂、部分反向激动剂),并且可以预见它们具有有趣的治疗应用前景。